Fully Human BCMA CAR T Cells for Durable Myeloma Cytolysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for multiple myeloma (MM) are limited by toxicity, inefficacy in relapsed or refractory cases, and challenges in targeting BCMA-positive tumor cells, leading to low survival rates and high side effects, especially for elderly or frail patients.

Innovation Solution

Development of fully-human BCMA chimeric antigen receptors (CARs) with high surface expression and cytolysis, transduced T cell expansion, and persistence, using novel antigen binding domains and signaling motifs to enhance T-cell therapy efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional combination therapies (thalidomide, bortezomib, lenalidomide) are used to treat multiple myeloma, then tumor cell killing activity is improved, but treatment-related toxicity increases significantly

Engineering Contradiction:

Improvetumor cell killing activityVSAvoidtreatment-related toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates BCMA as a specific target antigen on myeloma cells, separating the therapeutic action from non-specific tissue damage. By using CAR T-cells that specifically recognize and bind to BCMA, the therapy eliminates tumor cells while sparing normal tissues, thereby reducing treatment-related toxicity while maintaining tumor cell killing activity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces CAR T-cells as intermediary effector cells that mediate tumor cell killing through specific antigen recognition. The CAR T-cells serve as a bridge between the immune system and tumor cells, enabling targeted destruction of BCMA-positive cells without direct toxic damage to healthy tissues, thus resolving the contradiction between efficacy and toxicity.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If high dose chemotherapy with autologous stem cell transplant is used, then survival chances are improved, but medical risks and discomfort increase

Engineering Contradiction:

Improvesurvival chancesVSAvoidmedical risks and discomfort

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical/physical process of high-dose chemotherapy and stem cell transplant with a biological immune-based therapy. CAR T-cells utilize the immune system's natural cytotoxic mechanisms to destroy tumor cells, eliminating the need for harsh chemical chemotherapy and invasive transplant procedures, thereby reducing medical risks and discomfort while maintaining survival benefits.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Productivity

If murine-derived ScFv sequences are used in CAR construction, then initial binding activity is achieved, but in vivo CAR T persistence and function deteriorate due to anti-CAR immunity

Engineering Contradiction:

Improveinitial binding activityVSAvoidin vivo CAR T persistence

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent changes the critical parameter of antigen binding domain origin from murine-derived to fully human sequences. This parameter change eliminates immunogenicity against the CAR T-cells themselves, allowing the therapy to persist and function effectively in vivo without being targeted for destruction by the patient's immune system, thus resolving the contradiction between initial binding activity and long-term persistence.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The BCMA CARs provide specific and efficacious anti-tumor effects with improved T-cell expansion and persistence, reducing treatment-related toxicity and enhancing survival rates for BCMA-positive cancers.

Implementation Method 1

BCMA antigen binding domains and chimeric antigen receptors (CARs) containing such BCMA antigen binding domains

Methodology Applied

Scientific EffectAntigen binding:

Implementation Method 2

The CARs exhibit a high surface expression on transduced T cells, with a high degree of cytolysis and transduced T cell expansion and persistence

Methodology Applied

Scientific EffectCytolysis:

Data Source

PatentUS20260015403A1Compositions and methods for treating cancer with Anti-BCMA immunotherapy

Publication Date: 2026.01.15 LENTIGEN TECHNOLOGY INC

AI summary

Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.